Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Cash & Equivalents for 3 consecutive years, with $141.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 69.46% year-over-year to $141.9 million; the TTM figure through Dec 2025 stood at $141.9 million (down 69.46% YoY), while the FY2025 annual figure was $141.9 million, down 67.76% from the prior year.
• Cash & Equivalents fell to $141.9 million in Q4 2025 per TLX's latest filing, from $464.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $464.5 million in Q4 2024 and bottomed at $80.2 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $228.9 million across 3 years, with a median of $141.9 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 479.03% — and 2025, when it sank 69.46%.
• Telix Pharmaceuticals' Cash & Equivalents stood at $80.2 million in 2023, then surged by 479.03% to $464.5 million in 2024, then tumbled by 69.46% to $141.9 million in 2025.
• Business Quant data shows TLX's Cash & Equivalents at $141.9 million in Q4 2025, $464.5 million in Q4 2024, and $80.2 million in Q4 2023.